NCT06378892
Clinical Trial Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT06378892 |
| Title | A Study to Evaluate the Combination of Platinum-pemetrexed Based Chemotherapy Plus Lorlatinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) With Exclusively Extracranial Disease Progression on Lorlatinib (ALK-PPL) |
| Acronym | ALK-PPL |
| Recruitment | Recruiting |
| Gender | both |
| Phase | Phase II |
| Variant Requirements | Yes |
| Sponsors | Centro di Riferimento Oncologico - Aviano |
| Indications | |
| Therapies | |
| Age Groups: | adult | senior |
| Covered Countries | ITA |
CKB BOOST